

## NESTLÉ HEALTH SCIENCE SYMPOSIUM

ObesityWeek® 2024





Medical Director of the L-MARC, University of Louisville School of Medicine, Louisville, KY, USA

**DR** Harold Bays

## **ROLE OF NUTRITION INTERVENTION** IN THE AGE OF HIGHLY EFFECTIVE **ANTI-OBESITY MEDICATIONS (AOMs)**

## Fat-Free Mass (FFM) Fat Mass (FM) Bone **Understanding** Skeletal body composition changes Total **Body** Mass Lean body mass (LBM) is made up of skeletal muscle, Organs water and organs1 **Lean Body Skeletal Muscle** Mass (LBM) Mass (SMM) In GLP-1RA clinical Risk of sarcopenic obesity4 trials, proportion of ↓ muscle mass weight reduction ↓ muscle strength due to \ LBM is ↓ physical performance typically 25-60%2 à i Sarcopenic obesity risk factors<sup>5</sup> Popular diet programs Age are associated with around 25% reduction Inadequate protein/ nutrient intake in LBM as a Physical inactivity Low muscle mass percentage of total weight loss. Comorbidities Lowest LBM reduction Weight recycling (~11%) with high Caloric restriction protéin diet<sup>3</sup> Muscle wasting meds Muscle mass Measure Muscle strength Step devices MRI Motion devices Stair devices Walking distance test DEXA Sitting to standing test scan Preserve muscle mass during weight loss High Regular protein resistance training (e.g. 2x/week) diet



1. Nuijten MAH, Eijsvogels TMH, Monpellier VM, Janssen IMC, Hazebroek EJ, Hopman MTE. The magnitude and progress of lean body mass, fat-free mass, and skeletal muscle mass loss following bariatric surgery: A systematic review and meta-analysis. Obes Rev. 2022 Jan;23(1):e13370.

2. Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024 Sep;26 Suppl 4:16-27.

3. Willoughby D, Hewlings S, Kalman D. Body Composition Changes in weight loss: strategies and supplementation for maintaining lean body mass, a brief review. Nutrients. 2018 Dec 3;10(12):1876.

4. Smith C, Woessner MN, Sim M, Levinger I. Sarcopenia definition: Does it really matter? Implications for resistance training. Ageing Res Rev. 2022 Jun;78:101617.

5. Mechanick JI, Butsch WS, Christensen SM, Hamdy O, LI Z, Prado CM, Heymrigheld SB. Strategies for minimizing muscle loss during use of incretin-minieric drugs for treatment of obesity. Obes Rev. 2024 Sep 19:e13841.

6. Christensen S, Robinson K, Thomas S, Williams DR. Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: A narrative review and discussion of research needs. Obes Pillars. 2024 Jul 25;11:100121.